Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Clinical trial NCT04907344 · UNKNOWN
Trial details
- NCT number
- NCT04907344
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-15
- Primary completion
- 2025-06-30
- Enrollment
- 420
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.